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Induction of immune tolerance is a key process by which the immune system is educated to 
modulate reactions against benign stimuli such as self-antigens and commensal microbes. 
Understanding and harnessing the natural mechanisms of immune tolerance may become an 
increasingly useful strategy for treating many types of allergic and autoimmune diseases, as well 
as for improving the acceptance of solid organ transplants. Our laboratory and others have been 
interested in the natural ability of some B lymphocytes to express the death-inducing molecule 
Fas ligand (FasL), and their ability to kill T helper (TH) lymphocytes. We have recently shown that 
experimental transformation of human B cells by a non-replicative variant of Epstein-Barr virus 
(EBV) consistently resulted in high expression of functional FasL protein. The production and 
release of FasL+ exosomes that co-expressed major histocompatibility complex (MHC) class 
II molecules and had the capacity to kill antigen-specific TH cells was also observed. Several 
lines of evidence indicate that FasL+ B cells and FasL+MHCII+ exosomes have important roles 
in natural immune tolerance and have a great deal of therapeutic potential. Taken together, 
these findings suggest that EBV-immortalized human B lymphoblastoid cell lines could be 
used as cellular factories for FasL+ exosomes, which would be employed to therapeutically 
establish and/or regain immune tolerance toward specific antigens. The goals of this review 
are to summarize current knowledge of the roles of FasL+ B cells and exosomes in immune 
regulation, and to suggest methods of manipulating killer B cells and FasL+ exosomes for 
clinical purposes.
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IntroductIon
Fas ligand (FasL, CD178) is an important mediator of peripheral immune tolerance that is con-
stitutively expressed by specialized epithelial cells at immune privileged sites of the body such as 
the eye and reproductive organs (1–3). Within the immune system, FasL expression is most often 
attributed to cytotoxic CD8+ T lymphocytes (CTL) and natural killer (NK) cells that are activated 
in response to viral infections or malignancies (4–8). A requirement for FasL expression by CD8+ 
veto T cells leading to deletion of effector CTL has been demonstrated to enhance tolerance of 
transplanted bone marrow cells (4, 9). Interaction of FasL with its receptor Fas (CD95) initiates 
a signaling cascade that leads to programmed cell death (apoptosis) in susceptible target cells (10, 
11). The importance of FasL–Fas-mediated apoptosis to immune regulation was first highlighted 
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when T
H
 cells were mixed with purified B cells from worm-infected 
mice. In a follow-up study, it was discovered that FasL expression 
was present on 1–2% of splenic B lymphocytes in uninfected mice, 
and was almost exclusively found within the CD5+ B-cell subset 
(36). The number of CD5+ and CD5neg B cells that expressed FasL 
increased significantly during the acute phase of schistosome infec-
tion, paralleling increases in T
H
 cell apoptosis. Purified CD5+ B 
cells from both naïve and schistosome-infected mice had potent 
in vitro cytotoxic activity against T
H
 cells isolated from schistosome-
infected mice, but not naïve T
H
 cells. In summary, mouse CD5+ B 
cells are constitutive and inducible expressers of functional FasL, 
and are efficient killer cells toward antigen-specific T
H
 cells in vitro. 
It is yet to be determined if the human equivalents of CD5+ B cells, 
or other human B-cell subsets with reported regulatory functions, 
have the same constitutive expression of FasL and ability to kill 
antigen-specific T
H
 cells in vivo (37).
control of KIller B lymphocyte Growth and 
functIon
The schistosome model is an excellent system for studying the pro-
gression of the immune response. The initial reaction to worm 
egg deposition is an innate, pro-inflammatory reaction followed 
by acute T
H
1- and T
H
17-mediated inflammation that transitions 
to a strong T
H
2-mediated immune response, and which ultimately 
culminates in a chronic, fibrotic, and systemically immunosup-
pressive reaction (38). Peak FasL+ B-cell expansion and activation 
in the schistosome model occurred in the latter stages of the T
H
2 
response and beginning of the chronic phase (35). B cells isolated 
from infected mice could be further induced to express surface 
FasL by treatment with interleukin 4 (IL-4) and IL-10 (36). More 
recently, we have shown that in vitro activation of purified splenic 
B cells from naïve mice with CD40 ligand (CD40L) and the T
H
2 
cytokine IL-5 (but not IL-4) was sufficient to induce the prolif-
eration of CD5+FasL+ B cells, and to increase the peptide-specific 
by studies of mice with mutations affecting this pathway that 
developed lymphoproliferative disorders and produced autoan-
tibodies similar to those found in systemic lupus erythemato-
sus (SLE) patients (12, 13). In humans, defects in the FasL–Fas 
signaling pathway result in the autoimmune lymphoproliferative 
syndrome (ALPS), which most often manifests as autoimmune 
hemolytic anemia or other cytopenias caused by cell-specific 
autoantibody production (14). Thus, it is clear that FasL–Fas 
interactions play a significant role in regulating the production 
of pathogenic autoantibodies. It is well-established that mature B 
lymphocytes that have been activated through interactions with 
T helper (T
H
) lymphocytes are susceptible to FasL-mediated apo-
ptosis, and presumably receive this signal from the interacting 
T
H
 cell (15–17). What has often been overlooked is that some B 
lymphocytes express functional FasL constitutively, and that 
many types of stimuli can induce FasL expression in B cells (18). 
KEy concEpT 1 | Some B lymphocytes express functional FasL 
constitutively
In mice, these have been identified primarily within the CD5+ B-cell subset 
in spleen and lung. It remains to be determined how important they are in 
networks of mucosal and systemic immune tolerance, and which B-cell 
subset(s) in humans, if any, have similar functions.
Therefore, it is important to consider that the reciprocal induc-
tion of apoptosis mediated by the B cell against the T
H
 cell during 
these cognate interactions may also play a critical role in immune 
tolerance toward self-antigens.
fasl+ KIller B cells
Expression of FasL by B cells was first reported in 1996 by Hahne 
and Tschopp, who demonstrated that activation of mouse B cells by 
mitogens led to FasL expression and killing of Fas-sensitive target 
cells by B cells from wild-type mice but not from FasL-mutant 
mice (19). Several other reports confirmed expression of FasL by 
both human and mouse B cells (20–30). Notably, it was found that 
human B-cell expression of FasL was induced during human immu-
nodeficiency virus (HIV) and Epstein-Barr virus (EBV) infections, 
and that T
H
 cells from infected individuals were very sensitive to 
Fas-mediated apoptosis (21, 27). While these data suggested that 
FasL expression by B cells might play a pathogenic role by inducing 
T
H
 cell death in these viral infections, this was not explicitly tested. 
The first direct evidence that human B cells could induce T
H
 cell 
apoptosis was demonstrated using FasL+ B-chronic lymphocytic 
leukemia (B-CLL) cells to kill a susceptible CD4+ T-cell leukemia 
line (23). FasL expression is common in the aggressive form of 
B-CLL, and has been reported in other human B-cell leukemias and 
lymphomas, most notably, multiple myeloma (31–34). Important 
questions that remain regarding human FasL+ B cells include: 1) 
are there specific human B-cell subsets that preferentially express 
FasL; 2) how is FasL expression regulated in human B cells; and 
3) what are the normal functions of FasL+ B cells in humans? Studies 
performed in mice may provide some answers to these questions.
Analysis of T
H
 cell apoptosis and the cellular distribution of FasL 
expression in the schistosome worm infection model led to our 
independent discovery of mouse FasL+ B cells (35). In that study, 
antigen-specific T
H
 cell apoptosis was impaired when B cells but 
not CD8+ T cells were depleted from cell cultures, and was regained 
KEy concEpT 2 | Activation of purified splenic B cells from naïve mice 
with cD40 ligand (cD40L) and the TH2 cytokine IL-5 (but not IL-4) was 
sufficient to induce the proliferation of cD5+FasL+ B cells
This technique will be helpful for overcoming limitations in killer B-cell numbers 
and for studying the signaling requirements and in vivo effector functions of 
killer B cells in the future.
cytotoxic activity of B cells against T
H
 cells (39). Naïve splenic B cells 
stimulated with the combination of CD40L and IL-5 and IL-4 were 
actually inhibited in their surface FasL expression and killer func-
tion, despite expressing similar levels of intracellular FasL. These 
data demonstrate novel differences in killer B-cell responses to the 
T
H
2 cytokine milieu and suggest that intracellular sequestration of 
FasL is a mechanism that regulates killer B-cell function.
Until recently, IL-4 and IL-5 were generally accepted as cytokines 
produced by T
H
2 cells that have distinct but cooperative effects in 
driving T
H
2-mediated inflammation. However, a report by Islam 
et al. showed that IL-4 is an early activation product of T
H
2 cells 
and that chronically activated T
H
2 cells may switch to predominant 
production of IL-5 (40). It has also been reported that mucosal 
type 2 innate lymphoid cells (ILC2 cells) produce high levels of 
IL-5 compared to IL-4 when stimulated by IL-25 or IL-33, and 
are important contributors to T
H
2 inflammation. Interestingly, 
Lundy et al. Tolerance by killer B cells and exosomes
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CD5+ B cells are more abundant in the mucosa, where they are 
commonly referred to as B-1a cells, and are sparse in the lymph 
nodes or circulation. It is quite likely that B-1a cells receive signals 
from ILC2 cells under homeostatic and inflammatory conditions. 
Although it remains to be formally proven, such an interaction 
would be expected to support mucosa-associated FasL+CD5+ B cells 
(Figure 1A). This may have important implications for protection 
from food allergies and local mucosal inflammation, and could play 
a role in the broader systemic immune tolerance mediated through 
the mucosal immune system.
Mice with an X-linked functional mutation of Bruton’s tyrosine 
kinase (Xid mice) or IL-5 deficiency have a severe impairment 
of mucosal B-1a cells (41–43). These mice have provided use-
ful models to study the functions of CD5+ B cells in vivo. B-1a 
cells are a major source of natural antibodies, which are germline 
IgM immunoglobulins that are present at birth and which tend 
to have poly-reactive specificities for carbohydrates, lipids, and 
nucleic acids rather than protein components of antigens (44, 45). 
Interestingly, many of these germline-configured IgM antibodies 
also have a strong tendency to bind self-antigens (Figure 1B), and 
for this reason, B-1a cells have often been implicated as a source of 
autoantibodies and as contributors to autoimmune disease patho-
genesis (46). The likelihood that self-reactive CD5+ B cells may also 
constitutively express FasL suggests that their more common role 
in autoimmunity may be to eliminate other self-reactive B and T 
cells (Figures 1C,D), and thus protect against the development of 
autoimmune diseases (47).
fasl+ B cells and tolerance
Immune tolerance is an active and complex process by which 
potentially harmful self-reactive lymphocytes are either eliminated, 
shunted into permanently inactive (anergic) states, or induced to 
become specialized immune regulatory cells. Breakdowns in toler-
ance that occur either centrally during lymphocyte development, or 
peripherally during inflammatory responses can lead to hyperactive 
immune reactions and severe pathological consequences (48). As 
evidenced by the autoimmune pathology associated with Fas or 
FasL-deficiencies, this death pathway is critical to normal immune 
A
B
C
D
FIgurE 1 | Hypothesized interactions of killer B cells with other 
lymphocytes. Fas ligand (FasL) expression is constitutive on mouse spleen and 
lung CD5+IgMhigh B cells, which have been shown to kill antigen-specific TH cells 
in vitro. Co-activation of mouse B cells through CD40 and the IL-5 receptor led to 
proliferation of CD5+ B cells, increased surface expression of FasL and killer 
function, and production and release of IL-10. (A) Interactions of killer B cells 
with mucosal type 2 innate lymphoid cells (ILC2), or with chronically stimulated 
TH2 cells in vivo would be expected to support their growth and functions, but 
has not been formally proven. (B) Surface immunoglobulins on CD5+ B cells are 
poly-reactive and are known to recognize autoantigens that once bound can be 
internalized and processed into peptides, which are then presented to TH cells 
on class II major histocompatibility (MHCII) molecules. (c) Binding of an 
autoantigen simultaneously by a killer B cell and an effector B cell could be a 
mechanism to explain B-cell fratricide, which has been described in several 
reports. (D) Killer B-cell uptake and presentation of autoantigens to TH cells in 
the context of FasL–Fas signaling in vivo could lead to activation-induced cell 
death and is hypothesized to be an important mechanism for maintaining 
peripheral tolerance and preventing autoimmune diseases. These processes 
may also play a role in tolerance to food antigens, other allergens, and 
commensal microbes.
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tolerance (8). It is important to note that tolerance can also develop 
toward foreign antigens and is highly dependent on the location 
of antigen exposure and concurrent signals from the local envi-
ronment. The fetal–maternal interface, gut mucosa, other sites of 
immune privilege, and the microenvironments created by tumors 
are especially well-suited to induction of tolerance (49). While the 
relative importance of FasL+ B cells in immune tolerance has not 
been studied extensively, several reports support an in vivo role for 
killer B cells in immune regulation and the induction of tolerance.
Minagawa et al. demonstrated that tolerance toward male H-Y 
antigen could be generated in mice through adoptive transfer 
of male splenic B cells into female recipients (50). The authors 
went on to show that tolerance was dependent on functional Fas 
restrIctIons on fasl expressIon
Detection of FasL expression on the cell surface is usually not very 
robust, and most likely only represents a fraction of the total FasL 
protein produced by the cell. Cell types that do have measurable 
FasL on their surface, including B-1a cells, are often restricted in 
their distribution to specific niches where their interactions with 
Fas-sensitive target cells are more limited than if the FasL+ cells 
were allowed to circulate systemically. In cytotoxic T cells and NK 
cells, surface expression of FasL is transient due to the activity of 
metalloproteinases that cleave FasL and release the molecule in an 
inactive soluble form (61). Experimental systems in which FasL 
expression was forced to occur on cell surfaces, or in which cleav-
age of cell surface FasL was inhibited, most often resulted in the 
induction of target cell activation leading to inflammation rather 
than cell death (62–67). Moreover, the levels of transcription of the 
FasL gene in CTL and NK cells are very low in comparison to the 
amount of FasL protein found within the cells. This suggests that 
the FasL protein is fairly stable and is stored in the cell cytoplasm 
in a form that could be quickly transported to the cell surface when 
an appropriate target cell is identified.
In 1996, Martinez-Lorenzo and colleagues demonstrated that a 
preformed pool of FasL protein was sequestered within the cyto-
plasm of the immortalized human T-cell line, Jurkat (68). Upon 
stimulation, the FasL was rapidly released into the culture superna-
tant in a form that could induce cell death of other Jurkat T cells (68). 
In a subsequent study, these authors showed that bioactive FasL 
released by Jurkat was associated with microvesicles that could be 
removed by ultracentrifugation, and that similar FasL+ microvesi-
cles were produced by non-transformed human T cells (69). It is 
now understood that these microvesicles were FasL+ exosomes and 
that this finding could explain conflicting data regarding soluble 
FasL and its role in mediating activation-induced cell death.
KEy concEpT 3 | Tolerance toward male H-y antigen could be 
generated in mice through adoptive transfer of male splenic B cells 
into female recipients
This study by Minagawa et al. demonstrated that the tolerizing effect of 
transferred B cells was Fas ligand-dependent. This report supports the concept 
that killer B cells could be targeted therapeutically to induce immune tolerance.
receptor in the recipient mice, and that FasL on donor B cells was 
required (50). In separate studies, we showed that Xid mice, which 
lacked lung FasL+CD5+ B cells, failed to induce lung T
H
 cell apop-
tosis in a chronic airway allergen exposure model (51). Low T
H
 cell 
death in comparison to wild-type mice correlated with increased 
cytokine production, eosinophilia, and mucus production in the 
lungs despite high levels of IL-10 in the lung homogenates of the Xid 
mice (51). In the collagen-induced arthritis model, increased sever-
ity of joint inflammation correlated with decreased levels of FasL+ 
B cells in the spleen, and decreased killer function of B cells against 
antigen-specific T
H
 cells (47). Montandon et al. demonstrated that 
activation of bone marrow-derived pro-B cells via toll-like receptor 
9, induced pro-B-cell FasL expression, and that adoptive transfer of 
these cells into non-obese diabetic (NOD) mice resulted in protec-
tion from the spontaneous development of type 1 diabetes (52). An 
earlier study in NOD mice had also demonstrated a protective effect 
of B cells that were activated by bacterial lipopolysaccharide expo-
sure, and expressed both FasL and the anti-inflammatory cytokine, 
transforming growth factor beta (TGFβ) (53). Many other studies 
have demonstrated the ability of transferred CD5+ B cells to sup-
press immune responses and induce therapeutic tolerance, however, 
the focus of those reports was on the ability of CD5+ B cells to 
produce IL-10, and unfortunately, FasL production and function 
were not addressed (54–59). It would be interesting to repeat some 
of the above studies using IL-10-deficient, TGFβ-deficient, and 
FasL-deficient B cells to measure the relative importance of each 
molecule to the therapeutic efficacy of B cells.
We have recently reported that B cells isolated from tumor-
draining lymph nodes (TDLN) in a mouse breast tumor model 
were able to kill tumor cells in vitro and prevent metastases in vivo, 
and that B cells from IL-10-deficient mice were more potent killers 
of the tumor cells (60). FasL expression on TDLN B cells was not 
higher in the IL-10 knockout mice nor was there a difference in the 
total number of killer B cells. These data suggest that the lack of 
IL-10 from the adoptively transferred TDLN B cells may have had 
other inhibitory effects on B-cell killer functions, such as blocking 
critical interactions with the tumor cells and/or protective effects 
of IL-10 on the targeted tumor cells (60).
KEy concEpT 4 | Bioactive FasL released by Jurkat was associated 
with microvesicles that could be removed by ultracentrifugation
This study and others support the concept that killer cells package much of 
their Fas ligand into exosomes, which limits the expression of the protein 
on the cell surface, yet provides a ready pool of FasL that can be quickly 
released upon activation.
Exosomes are extracellular vesicles that are approximately 30–100 
nm in diameter, which are secreted by many types of cells,  including 
B cells and other hematopoietic cells (70, 71). Exosomes can be 
found in many types of bodily fluids (blood, breast milk, urine), 
and ultracentrifugation is required to separate them from soluble 
proteins. Truly soluble FasL protein, removed from the cell surface 
by metalloproteinase-mediated cleavage, must now be considered 
separately from exosomal FasL that is membrane bound (66, 72–74). 
Many studies showing that soluble FasL was inhibitory of cell death 
were most likely influenced by the presence in the tested samples of 
cleaved FasL protein. Soluble FasL does not cause Fas aggregation 
and may block binding of membrane-associated FasL with death-
inducing capacity. In contrast, exosomal FasL is very efficient at caus-
ing Fas aggregation, and may have been responsible for the results 
of those studies showing that “soluble” FasL was able to induce cell 
death. FasL+ exosomes are released by many types of FasL-producing 
cells, including NK cells, cytotoxic T cells, retinal pigment epithe-
lial cells, and placental trophoblasts (75–77). FasL+ tumor cells can 
also produce FasL+ exosomes that target tumor-specific CD8+ T 
Lundy et al. Tolerance by killer B cells and exosomes
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from the secretory lysosome where newly synthesized and recycled 
MHCII molecules are loaded with peptides derived from endo-
cytosed proteins (Figure 2) (81). Thus, exosomes derived from 
APC contain peptide-loaded MHCII and co-stimulatory mol-
ecules, and are capable of activating antigen-specific T
H
 cells (81). 
Unique to B cells is the fact that their APC function is restricted 
to antigens recognized by their surface immunoglobulins, which 
when bound to antigen are able to transfer the antigens directly to 
the secretory lysosomal compartment where MHCII+ exosomes 
are assembled (Figure 2) (82). In the case of an autoreactive B-1a 
cell that expresses FasL, we hypothesize that self-antigen uptake 
results in incorporation into MHCII+FasL+ exosomes (Figure 2). 
Subsequent binding of an autoreactive T
H
 cell to these autoantigen/
MHCII complexes and co-ligation by FasL either during cell–cell 
cells and aid in tumor immune escape (78). A direct demonstration 
that killer B cells can naturally produce FasL+ exosomes has not 
yet been reported, but it also has not been ruled out.
FasL+ exosomes circulating in normal human and mouse 
blood can co-express class II major histocompatibility complex 
(MHCII) molecules that are characteristic of professional anti-
gen-presenting cells (APC) (79, 80). In APC, exosomes originate 
FIgurE 2 | Membrane, exosome, and soluble forms of Fas ligand. Fas ligand 
(FasL) protein has been detected in several different forms in mouse and human 
cells and bodily fluids. Expression of FasL mRNA is generally low and the protein 
is assembled as a homotrimer in the trans-Golgi prior to transport to the cell 
surface. Plasma membrane expression of FasL is constitutive on a few 
specialized epithelial cell types at sites of immune privilege and on CD5+ B cells 
that have restricted localization. Cell surface expression of FasL is regulated by 
proteolytic cleavage by metalloproteinases, or by shunting of FasL protein into 
the secretory lysosomal compartment (SLC). Trafficking of FasL to the SLC is 
controlled by mono-ubiquitylation. The SLC is a site of antigen processing for 
molecules transported there from the cell surface by immunoglobulins, and 
processed peptides are loaded onto MHC class II (MHCII) molecules in the SLC. 
Through internal budding of the SLC membrane, FasL and MHCII are 
incorporated into exosomes that are stored in secretory vesicles of killer 
lymphocytes. Activation of the cell leads to their transport to the cell surface and 
release into the extracellular space.
KEy concEpT 5 | FasL+ exosomes circulating in normal human and 
mouse blood can co-express class II major histocompatibility complex 
(MHcII) molecules that are characteristic of professional antigen-
presenting cells (Apc)
The origin of these naturally occurring FasL+MHCII+ exosomes has not been 
positively identified and we hypothesize that killer B cells are one likely source.
Lundy et al. Tolerance by killer B cells and exosomes
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or cell–exosome interaction could then result in T
H
 cell death and 
induction of immune tolerance toward that self-antigen. Similar 
processes could be envisioned if the B-1a cells were specific for 
food allergens, commensal bacteria, or other antigens toward which 
immune tolerance was desired. The unique positioning of B-1a cells 
at mucosal surfaces favors their involvement in maintaining local 
mucosal tolerance through surface expression of FasL and direct 
interaction with local cells. Beyond that, if the mucosal B-1a cells 
also produce FasL+MHCII+ exosomes, this could be an important 
yet overlooked natural mechanism by which systemic tolerance to 
mucosa-associated antigens is induced and maintained without the 
need for killer B-cell circulation outside the mucosa.
fasl+ exosomes and Immune tolerance
The therapeutic application of exosomes has received increasing 
attention as a means to deliver signals to specific cell types, and 
as an alternative to adoptive immune cell therapy (83). Most of 
the efforts have been focused on using APC-derived exosomes to 
deliver activation signals for generating anti-tumor or anti-micro-
bial immune responses (84–86). However, some investigators have 
focused instead on the immune-tolerizing capacity of exosomes, 
with particular interest placed on FasL+MHCII+ exosomes (70, 
87). An early study showed that bone marrow-derived dendritic 
cells (BMDCs) genetically engineered to express FasL were able to 
produce FasL+MHCII+ exosomes that had direct killing effects on 
CD4+ T
H
 cells (88). Further studies revealed the presence of natu-
rally occurring FasL+MHCII+ exosomes in the blood of immunized 
mice, confirming the production of FasL+MHCII+ exosomes by 
non-transduced cells (80). Endogenously -produced FasL+MHCII+ 
exosomes mediated antigen-specific suppression of delayed-type 
hypersensitivity and experimental arthritis upon transfer to recipi-
ent mice (80). These naturally occurring FasL+MHCII+ exosomes 
did not express markers typical of BMDC-derived exosomes but 
did express CD11b, a surface molecule expressed by monocytes, 
macrophages, and mucosal B-1 cells. FasL+MHCII+ exosomes have 
also been found in human plasma, and had FasL-dependent sup-
pressive activity against CD4+ T cells (79). To date, human FasL+ 
killer B cells have not been positively identified, making it difficult 
to define markers that would allow one to conclude whether or not 
they are the source of naturally -occurring human FasL+MHCII+ 
exosomes. However, one of our recent investigations demonstrated 
a very robust method for experimentally producing human B- cell-
derived FasL+MHCII+ exosomes.
human B cells transformed By eBV produce fasl+ 
exosomes
In attempting to identify human B cells that produce FasL, our 
laboratory screened a panel of 20 EBV-transformed B lympho-
blastoid cell lines (B-LCL) that had been produced using the non-
replicative laboratory B95-8 EBV strain (89). This virus has been 
used for decades to produce immortalized human B-LCL for studies 
of antibody rearrangement and other B-cell functions, and there 
are likely to be thousands of B-LCL distributed throughout the 
world. Although individual B-LCL had previously been demon-
strated to express functional FasL, it was remarkable to find that 
every one of the lines we tested expressed a high amount of FasL 
protein. Despite easily detectable amounts of protein as measured 
by Western blots of whole cell lysates and intracellular staining, 
FasL protein was not present on the cell surface of the B-LCL (89). 
In keeping with what was noted above for other cell types that 
express FasL, we found that the B-LCL spontaneously produced 
and released FasL+MHCII+ exosomes that could be purified from 
the cell culture supernatant by ultracentrifugation (Figure 3) 
KEy concEpT 6 | B-LcL spontaneously produced and released 
FasL+MHcII+ exosomes that could be purified from the cell culture 
supernatant by ultracentrifugation
These exosomes had potent killer function in vitro against human TH cells 
that was both antigen- and FasL-dependent. The fact that every B-LCL that 
was tested did this suggests that EBV could be used to create FasL+ 
exosomes from any individual’s B cells.
(89). The B-LCL exosomes were then used to induce death of 
autologous T
H
 cells through  antigen-dependent and FasL-mediated 
mechanisms as demonstrated by the use of bacterial superantigen 
or an exogenously loaded tetanus toxoid peptide in the presence or 
absence of FasL-neutralizing antibodies (Figure 3) (89). We believe 
that these findings open up the possibility that B-LCL could be 
used as cellular factories for producing FasL+MHCII+ exosomes 
for use in patient-customized treatments for many types of hyper-
inflammatory conditions.
adVantaGes of B-lcl exosomes for therapy
Cellular immunotherapy mediated by adoptive transfer of regula-
tory lymphocytes has been shown to suppress autoimmune diseases 
and allergic responses in many mouse models (90–92). These meth-
ods hold promise and have given us tools to dissect the importance 
of the different cell types and factors involved in immune regula-
tion. However, many large hurdles remain in the translation of 
cellular immunotherapy into common clinical practice. Perhaps, 
the most important of these obstacles is that the transferred cells 
must be closely matched or identical to the MHC of the recipient 
in order to not be rejected. Ideally, this could be overcome if the 
transferred cells were autologous. The regulatory cells would have 
to be purified from patient blood, expanded in culture, quality-
tested, and then reinfused in such a way that they would be viable 
and have the desired therapeutic effect. This form of treatment 
would be very expensive and time consuming. Notably, a defect 
in the function of regulatory T or B cells may be central to the 
cause of the inflammatory condition being treated, and therefore, 
infusion of more of these flawed cells may not be therapeutically 
helpful. Live regulatory cells may also turn off regulatory functions 
after transfer, or worse, change phenotype and participate in the 
inflammatory reaction. Much important work is being done and 
should continue in order to solve these problems and make adoptive 
cellular immunotherapy a better therapeutic option.
As subcellular alternatives to regulatory cell transfers, 
FasL+MHCII+ exosomes may hold some distinct advantages. First 
among these is that the killing of target T
H
 cells by exosomes is not 
dependent on the presence of other cells. They also can be tailored 
to be antigen-specific and would be expected to only target a small 
subset of T
H
 cells, while sparing desirable T
H
 cells and protective 
immunity toward pathogenic microbes. Cell death induction by 
its nature is also likely to have more permanent or long-lasting 
effects in comparison to transfer of cells that express IL-10 or 
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 producing exosomes. B-LCL can be frozen and stored in liquid 
nitrogen for decades without losing the ability to grow in cell culture. 
Transformation of the patient’s own B cells would allow for long-
term propagation of the cells, scaling up of the culture as needed, 
and thus a potentially unlimited supply of FasL+ exosomes that 
would be 100% MHC-matched, and therefore, tolerated upon 
reinfusion into the patient. The plethora of lines that have already 
been transformed, frozen, and stored also  provides a large potential 
TGFβ which might only transiently modify the immune response. 
Exosomes lack the cellular machinery to switch their functions 
after transfer, and therefore, are much less likely to be turned off 
or to switch to a pathogenic role than are transferred regulatory 
cells (93). Exosomes have been reported to be functional even 
after long-term storage in low temperature freezers. This would 
suggest that once a batch of FasL+MHCII+ exosomes has been 
produced, isolated, and quality-tested, they could be banked in 
repositories until needed.
The EBV-transformation system that we utilized may provide 
some additional improvements over other methods of producing 
FasL+MHCII+ exosomes. The non-replicating, laboratory strain 
of the virus seems to be very efficient at transforming human B 
cells from any donor and activating their natural ability to express 
FasL. In our experience, these cells will grow indefinitely in cell 
culture and require relatively little labor to keep them healthy and 
FIgurE 3 | FasL+MHcII+ exosome production by EBV-transformed B-LcL. 
Epstein-Barr virus (EBV) has been used for many years to experimentally 
transform human B cells into immortalized B lymphoblastoid cell lines (B-LCL). 
The figure is a schematic of the methods recently employed to demonstrate the 
killer function of B-LCL-derived exosomes. Use of the non-replicative laboratory 
EBV strain, B95-8, resulted in consistent induction of FasL expression by 
transformed B-LCL. These B-LCL packaged FasL along with MHC class II 
molecules into exosomes that were then spontaneously released into 
supernatants of the B-LCL cultures grown in exosome-free media. Multiple 
rounds of centrifugation at increasing speeds removed cells, debris, and larger 
vesicles from the culture supernatant, which was then spun at 110,000 × g to 
pellet the exosome fraction. Resuspended exosomes were exposed to 
exogenous tetanus toxoid peptide or a bacterial superantigen, washed, and then 
added to cultures of autologous TH cells. The method resulted in TH cell death 
that was exosome and antigen-dependent, and FasL-mediated as demonstrated 
by the use of FasL-neutralizing antibodies.
KEy concEpT 7 | A potentially unlimited supply of FasL+ exosomes 
that would be 100% MHc-matched, and therefore, tolerated upon 
reinfusion into the patient
Clinical translation of adoptive immunotherapy, whether it be cellular or 
vesicular, would be streamlined if mismatched MHC could be avoided. The 
exosome production method we describe may overcome this and other 
important obstacles.
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not been tested, and is likely to be far off, the promising results from 
mouse models and their advantages over cellular immunotherapy 
as outlined above suggest that such a strategy may work and is 
worth further exploration.
enGIneerInG eBV for exosome therapIes
We envision that someday B-LCL-derived exosomes, such as those 
employed in our previous study, could be useful in several clinical 
applications. First, using the existing methods and the B95-8 strain 
of EBV, we would propose transforming B cells from the patients 
to be treated, isolating FasL+MHCII+ exosomes from cell cultures 
of these B-LCL and then loading them with exogenous peptides 
specific to the disease being targeted prior to infusion of autolo-
gous exosomes back into the patient (Figure 4A). Such a strategy, if 
repository of B-LCL that may closely match the MHC of the recipi-
ent patients, which could circumvent unexpected obstacles that 
might occur with transformation of a specific individual’s B cells.
Unlike the genetic manipulations that were required to force 
FasL expression in dendritic cells, the B-LCL spontaneously pro-
duce FasL+MHCII+ exosomes. By taking advantage of the natural 
ability of B cells to express functional FasL, EBV may promote its 
own survival and ability to persist in infected individuals. The fact 
that the non-replicating B95-8 laboratory strain is capable of driv-
ing FasL+MHCII+ exosome production is especially important since 
there are no active virions in the B-LCL culture, and therefore, little 
to no danger of transferring replicating EBV along with the exo-
some infusion. Although the direct application of B-LCL-generated 
FasL+ exosomes for use as immune-tolerizing agents in humans has 
A B C D
FIgurE 4 | potential therapeutic uses of B-LcL exosomes. Exosomes 
isolated from culture supernatants of EBV-transformed B-LCL were able to kill 
antigen-specific TH cells in vitro through a FasL-dependent mechanism. This 
schematic shows ways in which the B95-8 EBV strain might be used in its 
native form or genetically modified to manufacture customized B-LCL 
exosomes. (A) Unmodified virus could be used to generate autologous or 
allogeneic B-LCL that spontaneously produce FasL+MHCII+ exosomes. 
Replacement of MHC-bound peptides with exogenous peptides could be 
used to tailor the therapy toward specific antigens. (B) An alternative would be 
to modify the EBV genome to create B-LCL that express specific antigens 
linked to a lysosomal sorting sequence (LSS), which would target the proteins 
to the secretory lysosome where exosomes are assembled. (c) EBV 
engineered to express rearranged surface immunoglobulins (IgD or IgM) with 
known specificities onto exosomes may prove useful in targeting antigen-
specific B cells, cancer, or virus-infected cells. (D) Inhibition of FasL 
expression in B-LCL through the repressor miR-21 or other molecules 
introduced into the EBV genome would be expected to yield FasLneg 
exosomes that could be used as vaccine adjuvants. Combining these genetic 
manipulations may further enhance the therapeutic potential of B-LCL-derived 
exosomes.
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conclusIon
There is still a great deal of basic and translational research to 
be done before we can attempt to manipulate killer B cells or 
their FasL+ exosomes in clinical trials. Some of the major ques-
tions that remain are: (1) is it safe to boost killer B-cell function 
in vivo and (2) what is the best approach toward achieving that 
goal. Fundamental to this pursuit will be better knowledge of 
how killer B cells are normally regulated in the body, their role in 
maintaining immune homeostasis and preventing disease, and the 
interactions they have with other regulatory or pro-inflammatory 
immune cells. It may be that many of the current therapies and 
medications used to treat autoimmune diseases or allergies have 
an effect on killer B cells that has gone unnoticed. In the case of 
development of B-LCL exosomes for therapy, it is likely that new 
techniques and equipment will have to be developed in order to 
reliably scale-up production and purify B-LCL-derived exosomes 
to the point that they can be tested for safety and efficacy in 
human subjects.
Research focused on immune regulatory pathways has yielded a 
wealth of knowledge and a number of potential targets for therapy. 
Beyond the established roles of regulatory T cells and their sig-
nature cytokines IL-10 and TGFβ in immune regulation, it has 
become increasingly clear that a larger network of cells and factors 
exists that induce and maintain immune tolerance. Increasing 
evidence suggests that killer B cells and FasL+MHCII+ exosomes 
play important and potentially irreplaceable roles in immune tol-
erance networks as specific regulators of T
H
 cells. By increasing 
awareness of killer B cells and their therapeutic potential, we hope 
to foster interest in studying their biology and roles in human 
health and disease.
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